{'fraction_non_alphanumeric': 0.03880597014925373, 'fraction_numerical': 0.009950248756218905, 'mean_word_length': 5.2875, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Prognosis Varies by Intrinsic Tumor Subtype in Patients Treated with Ribociclib.

When added to standard endocrine therapy, cyclindependent kinase (CDK) 4/6 inhibitors significantly improve outcomes for patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. However, the benefits of CDK 4/6 inhibitor therapy are not uniform for all patients. The validation of new biomarkers that predict the likelihood of response to CDK 4/6 inhibition would allow oncologists to personalize treatment planning in this patient population. The analysis of pooled data from the phase III MONALEESA trials explored the role of intrinsic tumor subtype (luminal A, luminal B, HER2-enriched, normal-like, and basal-like) as a predictor of clinical outcomes in patients treated with endocrine therapy with or without ribociclib [1]. Aleix Prat, M.D., Ph.D., of the Hospital Clinic of Barcelona, presented results from the retrospective biomarker analysis.